Seminars in Nephrology
Volume 25, Issue 4 , Pages 252-260 , July 2005

Hypertension in Kidney Transplantation

References 

  1. Opelz G , Wujciak T , Ritz E . Association of chronic kidney graft failure with recipient blood pressure . Kidney Int . 1998;53:217–222
  2. Chobanian AV , Bakris GL , Black HR , et al.   The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (The JNC 7 Report) . JAMA . 2003;289:2560–2572
  3. Paul LC , Benediktsson H . Post-transplant hypertension and chronic renal failure . Kidney Int . 1995;48:34–37
  4. Sanders CE , Curtis JJ . Role of hypertension in chronic renal dysfunction . Kidney Int . 1995;48:43–47
  5. Djamali A , Premasathian N , Pirsch JD . Outcomes in kidney transplantation . Sem Nephrol . 2003;23:306–316
  6. Mailloux LU , Levey AS . Hypertension in patients with chronic renal disease . Am J Kidney Dis . 1998;32(suppl):120–141
  7. National Kidney Foundation . K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease . Am J Kidney Dis . 2004;43(suppl):176–182
  8. Whelton PK , He J , Appel LJ , et al.   Primary prevention of hypertension (Clinical and public health advisory from The National High Blood Pressure Education Program) . JAMA . 2002;288:1882–1888
  9. Pérez Fontán M , Rodriguez-Carmona A , García-Falcón T , et al.   Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation . Am J Kidney Dis . 1999;33:21–28
  10. Ducloux D , Motte G , Kribs M , et al.   Hypertension in renal transplantation (Donor and recipient risk factors) . Clin Nephrol . 2002;57:409–413
  11. Kasiske BL , Anjum S , Shah R , et al.   Hypertension after kidney transplantation . Am J Kidney Dis . 2004;43:1071–1081
  12. Klein IH , Abrahams A , van Ede T , et al.   Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects . Transplantation . 2002;73:732–736
  13. Vincenti F , Jensik SC , Filo RS , et al.   A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation (Evidence for improved graft survival at 5 years) . Transplantation . 2002;73:775–782
  14. Margreiter R  for the European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group . Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation (A randomised multicentre study) . Lancet . 2002;359:741–746
  15. Ligtenberg G , Hené RJ , Blankestijn PJ , et al.   Cardiovascular risk factors in renal transplanted patients (Cyclosporine versus tacrolimus) . J Am Soc Nephrol . 2001;12:368–373
  16. Midtvedt K , Neumayer HH . Management strategies for posttransplant hypertension . Transplantation . 2000;70(suppl):64–69
  17. Koomans HA , Ligtenberg G . Mechanisms and consequences of arterial hypertension after renal transplantation . Transplantation . 2001;72(suppl):9–12
  18. Veenstra DL , Best JH , Hornberger J , et al.   Incidence and long-term cost of steroid-related side effects after renal transplantation . Am J Kidney Dis . 1999;33:829–839
  19. Hricik DE , Lautman J , Bartucci MR , et al.   Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients . Transplantation . 1992;53:1232–1235
  20. Johnson RW , Kreis H , Oberbauer R . Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure . Transplantation . 2001;72:777–786
  21. Hricik DE . Use of sirolimus to facilitate cyclosporine avoidance or steroid withdrawal in kidney transplant recipients . Transplant Proc . 2003;35(suppl):73–78
  22. Legendre C , Campistol JM , Squifflet JP , et al.   Cardiovascular risk factors of sirolimus compared with cyclosporine (Early experience from two randomized trials in renal transplantation) . Transplant Proc . 2003;35(suppl):151–153
  23. Hricik DE , Knauss TC , Bodziak KA , et al.   Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus . Transplantation . 2003;76:938–942
  24. Oberbauer R , Kreis H , Johnson RW , et al.   Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients (2-year results of the Rapamune Maintenance Regimen Study) . Transplantation . 2003;76:364–370
  25. Bruno S , Remuzzi G , Ruggenenti P . Transplant renal artery stenosis . J Am Soc Nephrol . 2004;15:134–141
  26. Buturovic-Ponkivar J . Renal transplant artery stenosis . Nephrol Dial Transplant . 2003;18:74–77
  27. Sharafuddin MJ , Stolpen AH , Dixon BS , et al.   Value of MR angiography before percutaneous transluminal renal artery angioplasty and stent placement . J Vasc Interv Radiol . 2002;13:901–908
  28. Guzman-Rodriguez JH , Plata-Munoz JJ , Mancilla E , et al.   Renal artery stenosis after transplantation (treatment using percutaneous transluminal angioplasty and placement of an expandable metal luminal prosthesis) . Rev Invest Clin . 2003;55:297–304
  29. Butler JA , Roderick P , Mullee M , et al.   Frequency and impact of nonadherence to immunosuppressants after kidney transplantation (A systematic review) . Transplantation . 2004;77:769–789
  30. Loghman-Adham M . Medication noncompliance in patients with chronic disease (Issues in dialysis and renal transplantation) . Am J Manag Care . 2003;9:155–171
  31. Ramos EL , Kasiske BL , Alexander SR , et al.   The evaluation of candidates for renal transplantation (The current practice of US transplant centers) . Transplantation . 1994;57:490–497
  32. Chapman JR . Compliance (The patient, the doctor, and the medication?) . Transplantation . 2004;77:782–786
  33. Frei U , Schindler R , Wieters D , et al.   Pre-transplant hypertension A major risk factor for chronic progressive renal allograft dysfunction? . Nephrol Dial Transplant . 1995;10:1206–1211
  34. Mange KC , Cizman B , Joffe M , et al.   Arterial hypertension and renal allograft survival . JAMA . 2000;283:633–638
  35. Budde K , Waiser J , Fritsche L , et al.   Hypertension in patients after renal transplantation . Transplant Proc . 1997;29:209–211
  36. Cosio FG , Falkenhain ME , Pesavento TE , et al.   Relationship between arterial hypertension and renal allograft survival in African American patients . Am J Kidney Dis . 1997;29:419–427
  37. Peschke B , Scheuermann EH , Geiger H , et al.   Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients . Clin Nephrol . 1999;51:290–299
  38. Cosio FG , Pelletier RP , Pesavento TE , et al.   Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients . Kidney Int . 2001;59:1158–1164
  39. Wheeler DC , Steiger J . Evolution and etiology of cardiovascular disease in renal transplant recipients . Transplantation . 2000;70(suppl):41–45
  40. Kasiske BL , Chakkera HA . Explained and unexplained ischemic heart disease risk after renal transplantation . J Am Soc Nephrol . 2000;11:1735–1743
  41. Schnuelle P , Lorenz D , Trede M , et al.   Impact of renal cadaveric transplantation on survival in end-stage renal failure (Evidence for reduced mortality risk compared with hemodialysis during long-term follow-up) . J Am Soc Nephrol . 1998;9:2135–2141
  42. Ojo A , Wolfe RA , Agodoa LY , et al.   Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation (Multivariate analyses from the United States Renal Data System) . Transplantation . 1998;66:1651–1659
  43. Ojo A , Hanson JA , Meier-Kriesche HU , et al.   Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates . J Am Soc Nephrol . 2001;12:589–597
  44. Meier-Kriesche HU , Ojo A , Port FK , et al.   Survival improvement among patients with end-stage renal disease . J Am Soc Nephrol . 2001;12:1293–1296
  45. Ojo A , Hanson JA , Wolfe RA , et al.   Long-term survival in renal transplant with graft function . Kidney Int . 2000;57:307–313
  46. Ponticelli C , Villa M , Cesana B . Risk factors for late kidney allograft failure . Kidney Int . 2002;62:1848–1854
  47. Lindholm A , Dagfinn A , Frödin L , et al.   Ischemic heart disease—major cause of death and graft loss after renal transplantation in Scandinavia . Transplantation . 1995;60:451–457
  48. Rashid Qureshi A , Alvestrand A , Divino-Fihlo  , et al.   Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients . J Am Soc Nephrol . 2002;13(suppl):28–36
  49. Varagunam M , Finney H , Trevitt R . Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients . Am J Kidney Dis . 2004;43:502–507
  50. Bakri RS , Afzali B , Covic A , et al.   Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation . Clin Transplant . 2004;18:201–204
  51. Zoccali C , Mallamaci F , Tripepi G . Novel cardiovascular risk factors in end stage renal disease . J Am Soc Nephrol . 2004;15(suppl):77–80
  52. McGregor E , Jardine AG , Murray LS , et al.   Pre-operative echocardiographic abnormalities and adverse outcome following renal transplantation . Nephrol Dial Transplant . 1998;13:1499–1505
  53. Ferreira SRC , Moisés VA , Tavares A , et al.   Cardiovascular effects of successful renal transplantation (A 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile) . Transplantation . 2002;74:1580–1587
  54. Mcmahon LP , Roger SD , Levin A . Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease . J Am Soc Nephrol . 2004;15:1640–1647
  55. Rigatto C , Foley R , Jeffery J , et al.   Electrocardiographic left ventricular hypertrophy in renal transplant recipients (Prognostic value and impact of blood pressure and anemia) . J Am Soc Nephrol . 2003;14:462–468
  56. Verdecchia P , Porcellati C , Schillaci G , et al.   Ambulatory blood pressure (An independent predictor of prognosis in essential hypertension) . Hypertension . 1994;24:793–801
  57. Fernández-Vega F , Tejada F , Baltar J , et al.   Ambulatory blood pressure after renal transplantation . Nephrol Dial Transplant . 2001;16(suppl):110–113
  58. Tomson CRV . Ambulatory blood pressure measurement in kidney transplantation (An overview) . Transplantation . 2003;15:1643–1644
  59. Covic A , Goldsmith DJ , Gusbeth-Tatomir P , et al.   What added value does ambulatory blood pressure monitoring brings to the management of post renal transplantation hypertension? . Rev Med Chir Soc Med Nat Iasi . 2003;107:89–97
  60. Kooman JP , Christiaans MH , Boots JM , et al.   A comparison between ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy . Am J Kidney Dis . 2001;37:1170–1176
  61. Covic A , Segal L , Goldsmith DJA . Ambulatory blood pressure monitoring in renal transplantation (Should ABPM be routinely performed in renal transplant patients?) . Transplantation . 2003;76:1640–1642
  62. Gatzka CD , Schobel HP , Klingbeil AU , et al.   Normalization of circadian blood pressure profiles after renal transplantation . Transplantation . 1995;59:1270–1274
  63. National Kidney Foundation . K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease . Am J Kidney Dis . 2004;43(suppl):252–261
  64. Dawidson I , Lu C , Palmer B , et al.   Verapamil (VP) improves the outcome after renal transplantation (CRT) . Transplant Int . 1992;5(suppl):60–62
  65. Rodicio JL . Calcium antagonists and renal protection from cyclosporine nephrotoxicity (Long-term trial in renal transplantation patients) . J Cardiovasc Pharmacol . 2000;35(suppl):7–11
  66. Citterio F , Serino F , Pozzetto U , et al.   Verapamil improves Sandimmune immunosuppression, reducing acute rejection episodes . Transplant Proc . 1996;28:2174–2176
  67. Boom H , Mallat MJ , de Fijter JW , et al.   Calcium levels as a risk factor for delayed graft function . Transplantation . 2004;77:868–873
  68. Raman GV , Feehally J , Coates RA , et al.   Renal effects of amlodipine in normotensive renal transplant recipients . Nephrol Dial Transplant . 1999;14:384–388
  69. Midvedt  , Hartman A , Holdaas H , et al.   Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation (A double blind randomized comparative study) . Clin Transplant . 2001;15:426–431
  70. Davidson MH . Does differing metabolism by cytochrome p450 have clinical importance? . Curr Atheroscler Rep . 2000;2:14–19
  71. Ruggenenti P , Perna A , Gheradi G , et al.   Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril (REIN follow-up trial) . Lancet . 1998;352:1352–1356
  72. Maschio G , Alberti D , Junin G , et al.   Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency . The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med . 1996;334:939–945
  73. Lewis EJ , Hunsicker LG , Bain RP . The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy . N Engl J Med . 1993;329:1456–1462
  74. National Kidney Foundation . K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease . Am J Kidney Dis . 2004;43(supp):1–290
  75. Shihab FS , Tanner AM , Shao Y , et al.   Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection . Kidney Int . 1996;50:1904–1913
  76. Lee DB . Cyclosporine and the renin-angiotensin axis . Kidney Int . 1997;52:248–260
  77. Border WA , Noble NA . Transforming growth factor beta in tissue fibrosis . N Engl J Med . 1994;331:1286–1292
  78. Yamada K , Hatakeyama E , Arita S , et al.   Prediction of chronic renal allograft dysfunction from evaluations of TGF Beta1 and the renin-angiotensin system . Clin Exp Nephrol . 2003;7:238–242
  79. Stigant CE , Cohen J , Vivera M , et al.   ACE inhibitors and angiotensin II antagonists in renal transplantation (An analysis of safety and efficacy) . Am J Kidney Dis . 2000;35:58–63
  80. Lewis JB , Helderman JH . Is it time for ACE inhibitors in chronic allograft nephropathy? . Am J Kidney Dis . 2000;35:154–156
  81. Inigo P , Campistol JM , Saracho R , et al.   Renoprotective effects of losartan in renal transplant recipients . Nephron Clin Pract . 2003;95:73–74
  82. Murray BM , Venuto RC , Kohli R , et al.   Enalapril-associated acute renal failure in renal transplants (Possible role of cyclosporine) . Am J Kidney Dis . 1990;16:66–69
  83. Garcia TM , da Costa JA , Costa RS , et al.   Acute tubular necrosis in kidney transplant patients treated with enalapril . Ren Fail . 1994;16:419–423
  84. Blumenfeld JD , Catanzaro DF , Kinkhabwala M , et al.   Renin system activation and delayed function of the renal transplant . Am J Hypertens . 2001;14:1270–1272
  85. Lorenz M , Billensteiner E , Bodingbauer M , et al.   The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function . Am J Kidney Dis . 2004;43:1065–1070
  86. Klingbeil AU , Schneider M , Martus P , et al.   A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension . Am J Med . 2003;115:41–46
  87. Suwelack B , Gerhardt U , Hausberg M , et al.   Comparison of quinapril versus atenolol (Effects on blood pressure and cardiac mass after renal transplantation) . Am J Cardiol . 2000;86:583–585
  88. Isobe N , Taniguchi K , Oshima S , et al.   Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease . Circ J . 2002;66:993–999
  89. Dahlöf B , Devereux RB , Kjeldsen SE . Cardiovascular morbidity and mortality in the losartan intervention for end point reduction in hypertension study (LIFE) (A randomized trial against atenolol) . Lancet . 2002;359:995–1003
  90. Hausberg M , Barenbrock M , Hohage H , et al.   Ace inhibitor versus β-blocker for the treatment of hypertension in renal allograft recipients . Hypertension . 1999;33:862–868
  91. Suwelak B , Kobelt V , Erfmann M , et al.   Long-term follow-up of ACE-inhibitor versus β-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients . Transplant Int . 2003;16:313–320
  92. Menon V , Sarnak MJ . Treating the patient with kidney failure to reduce cardiovascular disease risk . Curr Treat Options Cardiovasc Med . 2004;6:257–268
  93. Donahoo WT , Kosmiski LA , Eckel RH . Drugs causing dyslipoproteinemia . Endocrinol Metab Clin North Am . 1998;27:677–697
  94. Gress TW , Nieto FJ , Shahar E , et al.   Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus . Atherosclerosis Risk in Communities Study. N Engl J Med . 2000;342:905–912
  95. Ciancio G , Burke GW , Gaynor JJ , et al.   A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year . Transplantation . 2004;77:252–258
  96. Bell DS . Advantages of a third-generation beta-blocker in patients with diabetes mellitus . Am J Cardiol . 2004;93:49–52

PII: S0270-9295(05)00034-3

doi: 10.1016/j.semnephrol.2005.02.009

Seminars in Nephrology
Volume 25, Issue 4 , Pages 252-260 , July 2005

Article Tools

* Image Usage & Resolution